Myelin oligodendrocyte glycoprotein peptide–major histocompatibility complex class II complex (MOG peptide–MHC class II complex)

The myelin oligodendrocyte glycoprotein peptide–major histocompatibility complex class II complex is formed when a peptide epitope derived from MOG is bound and presented by an MHC class II molecule, typically on antigen-presenting cells like dendritic cells, B cells, or macrophages. This complex is essential for antigen recognition by CD4⁺ T helper cells, which orchestrate immune responses against central nervous system antigens. In autoimmune diseases such as multiple sclerosis and animal models like EAE, the formation and presentation of the MOG peptide–MHC class II complex drive pathogenic T cell activation, chronic inflammation, and demyelination of nervous tissue[5][2]. The peptide–MHC class II interaction is highly specific and governed by the binding groove's affinity for particular peptide residues and allelic variants, which further influence disease susceptibility and progression[5][3].

Other names

MOG–MHC II complexMOG antigen-MHC II complexMOG peptide–HLA class II complex (in humans)MOG+MHC II complex

Blocking antigen presentation (therapeutics may interfere with peptide loading, MHC II surface expression, or T cell recognition); Immune tolerance induction (e.g., altered peptide ligands); Immunosuppression (e.g., corticosteroids; indirect)